Abstract
Purpose: Stereotactic body radiotherapy (SBRT) for prostate cancer is delivered over a shorter period than standard fractionation, with similar levels of post-treatment toxicity [1]. However, the greater dose per fraction delivered increases the significance of inter-fraction variability. The use of prostate tracking devices in planning and during treatment may help reduce variability and help develop more personalised radiotherapy plans. Here, we present acute toxicity data for patients treated with SBRT for prostate cancer where on-treatment prostate tracking was carried out.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call